

To develop the lead of a new oral drug for age-related macular degeneration

Kyungpook National University Hospital



OPHTHALMOLOGY	Hit
Product Type	Chemical Product
Indication	Age-related macular degeneration
Target	PDK inhibitor
MoA(Mechanism of Action)	<ul style="list-style-type: none"> • PDK inhibitor suppresses PDHE1 phosphorylation and activates PDC. Improving the mitochondrial function of retinal cells that are metabolically reprogrammed by inflammatory and hypoxic environment, alleviates neovascularization by reducing overexpressed HIF-1α and VEGF.
Competitiveness	<ol style="list-style-type: none"> 1. Currently, there are no available oral medications for neovascular age-related macular degeneration. Furthermore, there are no PDK inhibitors developed for indications for ophthalmic diseases. 2. An oral preparation will relieve patients' fear and the incidence of complication. Additionally, less frequent visits by oral medication will reduce the medical cost and financial burden.
Development Stage	Hit
Route of Administration	Oral medication